These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 36625583)

  • 1. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.
    Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A
    Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
    mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
    Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
    Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
    Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and evolution of
    Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
    mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
    Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
    Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
    J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 16. CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.
    Gifford AH; Heltshe SL; Goss CH
    Ann Am Thorac Soc; 2019 Mar; 16(3):331-340. PubMed ID: 30580531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of CFTR modulators in special populations, part 2: Severe lung disease.
    Elijah J; Fitzgerald LJ; Phan H
    Pediatr Pulmonol; 2023 Dec; 58(12):3386-3392. PubMed ID: 37728222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.
    Ribeiro CMP; Higgs MG; Muhlebach MS; Wolfgang MC; Borgatti M; Lampronti I; Cabrini G
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.